nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—ADRB1—stomach cancer	0.441	0.543	CbGaD
Salbutamol—ADRB2—stomach cancer	0.37	0.457	CbGaD
Salbutamol—Isoprenaline—MAPK1—stomach cancer	0.000656	0.0736	CrCbGaD
Salbutamol—Pirbuterol—ADRB1—stomach cancer	0.000601	0.0673	CrCbGaD
Salbutamol—Levobunolol—ADRB1—stomach cancer	0.000535	0.06	CrCbGaD
Salbutamol—Pirbuterol—ADRB2—stomach cancer	0.000505	0.0566	CrCbGaD
Salbutamol—Isoetarine—ADRB1—stomach cancer	0.000471	0.0528	CrCbGaD
Salbutamol—Carteolol—ADRB1—stomach cancer	0.000455	0.051	CrCbGaD
Salbutamol—Levobunolol—ADRB2—stomach cancer	0.00045	0.0505	CrCbGaD
Salbutamol—Terbutaline—ADRB2—stomach cancer	0.000412	0.0462	CrCbGaD
Salbutamol—Nadolol—ADRB1—stomach cancer	0.000406	0.0455	CrCbGaD
Salbutamol—Isoetarine—ADRB2—stomach cancer	0.000396	0.0444	CrCbGaD
Salbutamol—Clenbuterol—ADRB1—stomach cancer	0.000391	0.0439	CrCbGaD
Salbutamol—Bupranolol—ADRB1—stomach cancer	0.000387	0.0434	CrCbGaD
Salbutamol—Carteolol—ADRB2—stomach cancer	0.000383	0.0429	CrCbGaD
Salbutamol—Clenbuterol—TNF—stomach cancer	0.000371	0.0416	CrCbGaD
Salbutamol—Salmeterol—ADRB2—stomach cancer	0.00035	0.0393	CrCbGaD
Salbutamol—Nadolol—ADRB2—stomach cancer	0.000341	0.0383	CrCbGaD
Salbutamol—Clenbuterol—ADRB2—stomach cancer	0.000329	0.0369	CrCbGaD
Salbutamol—Bupranolol—ADRB2—stomach cancer	0.000325	0.0365	CrCbGaD
Salbutamol—Isoprenaline—ADRB1—stomach cancer	0.000196	0.0219	CrCbGaD
Salbutamol—Norepinephrine—ADRB1—stomach cancer	0.000181	0.0203	CrCbGaD
Salbutamol—Isoprenaline—ADRB2—stomach cancer	0.000165	0.0185	CrCbGaD
Salbutamol—Epinephrine—ADRB1—stomach cancer	0.000164	0.0184	CrCbGaD
Salbutamol—Epinephrine—TNF—stomach cancer	0.000156	0.0175	CrCbGaD
Salbutamol—Norepinephrine—ADRB2—stomach cancer	0.000152	0.0171	CrCbGaD
Salbutamol—Epinephrine—ADRB2—stomach cancer	0.000138	0.0155	CrCbGaD
Salbutamol—Immune system disorder—Methotrexate—stomach cancer	0.000129	0.000727	CcSEcCtD
Salbutamol—Dizziness—Fluorouracil—stomach cancer	0.000129	0.000727	CcSEcCtD
Salbutamol—Mediastinal disorder—Methotrexate—stomach cancer	0.000129	0.000726	CcSEcCtD
Salbutamol—Rash—Irinotecan—stomach cancer	0.000128	0.000724	CcSEcCtD
Salbutamol—Dermatitis—Irinotecan—stomach cancer	0.000128	0.000723	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000128	0.000723	CcSEcCtD
Salbutamol—Chills—Methotrexate—stomach cancer	0.000128	0.000723	CcSEcCtD
Salbutamol—Headache—Irinotecan—stomach cancer	0.000127	0.000719	CcSEcCtD
Salbutamol—Hypotension—Capecitabine—stomach cancer	0.000127	0.000718	CcSEcCtD
Salbutamol—Insomnia—Docetaxel—stomach cancer	0.000127	0.000718	CcSEcCtD
Salbutamol—Paraesthesia—Docetaxel—stomach cancer	0.000126	0.000713	CcSEcCtD
Salbutamol—Dyspnoea—Docetaxel—stomach cancer	0.000125	0.000708	CcSEcCtD
Salbutamol—Somnolence—Docetaxel—stomach cancer	0.000125	0.000706	CcSEcCtD
Salbutamol—Mental disorder—Methotrexate—stomach cancer	0.000125	0.000706	CcSEcCtD
Salbutamol—Tinnitus—Epirubicin—stomach cancer	0.000124	0.000703	CcSEcCtD
Salbutamol—Malnutrition—Methotrexate—stomach cancer	0.000124	0.000701	CcSEcCtD
Salbutamol—Haemoglobin—Doxorubicin—stomach cancer	0.000124	0.000701	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000124	0.0007	CcSEcCtD
Salbutamol—Flushing—Epirubicin—stomach cancer	0.000124	0.000699	CcSEcCtD
Salbutamol—Cardiac disorder—Epirubicin—stomach cancer	0.000124	0.000699	CcSEcCtD
Salbutamol—Vomiting—Fluorouracil—stomach cancer	0.000124	0.000699	CcSEcCtD
Salbutamol—Rhinitis—Doxorubicin—stomach cancer	0.000124	0.000699	CcSEcCtD
Salbutamol—Dyspepsia—Docetaxel—stomach cancer	0.000124	0.000699	CcSEcCtD
Salbutamol—Haemorrhage—Doxorubicin—stomach cancer	0.000123	0.000697	CcSEcCtD
Salbutamol—Insomnia—Capecitabine—stomach cancer	0.000123	0.000695	CcSEcCtD
Salbutamol—Hypoaesthesia—Doxorubicin—stomach cancer	0.000123	0.000694	CcSEcCtD
Salbutamol—Rash—Fluorouracil—stomach cancer	0.000123	0.000693	CcSEcCtD
Salbutamol—Dermatitis—Fluorouracil—stomach cancer	0.000123	0.000693	CcSEcCtD
Salbutamol—Pharyngitis—Doxorubicin—stomach cancer	0.000123	0.000692	CcSEcCtD
Salbutamol—Paraesthesia—Capecitabine—stomach cancer	0.000122	0.00069	CcSEcCtD
Salbutamol—Decreased appetite—Docetaxel—stomach cancer	0.000122	0.00069	CcSEcCtD
Salbutamol—Headache—Fluorouracil—stomach cancer	0.000122	0.000689	CcSEcCtD
Salbutamol—Urinary tract disorder—Doxorubicin—stomach cancer	0.000122	0.000689	CcSEcCtD
Salbutamol—Dysgeusia—Methotrexate—stomach cancer	0.000122	0.000687	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000121	0.000685	CcSEcCtD
Salbutamol—Connective tissue disorder—Doxorubicin—stomach cancer	0.000121	0.000685	CcSEcCtD
Salbutamol—Dyspnoea—Capecitabine—stomach cancer	0.000121	0.000685	CcSEcCtD
Salbutamol—Fatigue—Docetaxel—stomach cancer	0.000121	0.000684	CcSEcCtD
Salbutamol—Angiopathy—Epirubicin—stomach cancer	0.000121	0.000684	CcSEcCtD
Salbutamol—Urethral disorder—Doxorubicin—stomach cancer	0.000121	0.000684	CcSEcCtD
Salbutamol—Nausea—Irinotecan—stomach cancer	0.000121	0.000682	CcSEcCtD
Salbutamol—Immune system disorder—Epirubicin—stomach cancer	0.000121	0.000681	CcSEcCtD
Salbutamol—Mediastinal disorder—Epirubicin—stomach cancer	0.00012	0.000679	CcSEcCtD
Salbutamol—Pain—Docetaxel—stomach cancer	0.00012	0.000679	CcSEcCtD
Salbutamol—Constipation—Docetaxel—stomach cancer	0.00012	0.000679	CcSEcCtD
Salbutamol—Back pain—Methotrexate—stomach cancer	0.00012	0.000678	CcSEcCtD
Salbutamol—Dyspepsia—Capecitabine—stomach cancer	0.00012	0.000677	CcSEcCtD
Salbutamol—Chills—Epirubicin—stomach cancer	0.00012	0.000676	CcSEcCtD
Salbutamol—Arrhythmia—Epirubicin—stomach cancer	0.000119	0.000673	CcSEcCtD
Salbutamol—Decreased appetite—Capecitabine—stomach cancer	0.000118	0.000668	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000118	0.000664	CcSEcCtD
Salbutamol—Fatigue—Capecitabine—stomach cancer	0.000117	0.000663	CcSEcCtD
Salbutamol—Mental disorder—Epirubicin—stomach cancer	0.000117	0.00066	CcSEcCtD
Salbutamol—Pain—Capecitabine—stomach cancer	0.000116	0.000657	CcSEcCtD
Salbutamol—Constipation—Capecitabine—stomach cancer	0.000116	0.000657	CcSEcCtD
Salbutamol—Malnutrition—Epirubicin—stomach cancer	0.000116	0.000656	CcSEcCtD
Salbutamol—Feeling abnormal—Docetaxel—stomach cancer	0.000116	0.000654	CcSEcCtD
Salbutamol—Nausea—Fluorouracil—stomach cancer	0.000116	0.000653	CcSEcCtD
Salbutamol—Ill-defined disorder—Methotrexate—stomach cancer	0.000115	0.00065	CcSEcCtD
Salbutamol—Tinnitus—Doxorubicin—stomach cancer	0.000115	0.00065	CcSEcCtD
Salbutamol—Gastrointestinal pain—Docetaxel—stomach cancer	0.000115	0.000649	CcSEcCtD
Salbutamol—Cardiac disorder—Doxorubicin—stomach cancer	0.000115	0.000647	CcSEcCtD
Salbutamol—Flushing—Doxorubicin—stomach cancer	0.000115	0.000647	CcSEcCtD
Salbutamol—Flatulence—Epirubicin—stomach cancer	0.000114	0.000646	CcSEcCtD
Salbutamol—Tension—Epirubicin—stomach cancer	0.000114	0.000644	CcSEcCtD
Salbutamol—Dysgeusia—Epirubicin—stomach cancer	0.000114	0.000642	CcSEcCtD
Salbutamol—Nervousness—Epirubicin—stomach cancer	0.000113	0.000637	CcSEcCtD
Salbutamol—Back pain—Epirubicin—stomach cancer	0.000112	0.000635	CcSEcCtD
Salbutamol—Feeling abnormal—Capecitabine—stomach cancer	0.000112	0.000633	CcSEcCtD
Salbutamol—Angiopathy—Doxorubicin—stomach cancer	0.000112	0.000633	CcSEcCtD
Salbutamol—Malaise—Methotrexate—stomach cancer	0.000112	0.000632	CcSEcCtD
Salbutamol—Muscle spasms—Epirubicin—stomach cancer	0.000112	0.000631	CcSEcCtD
Salbutamol—Immune system disorder—Doxorubicin—stomach cancer	0.000112	0.00063	CcSEcCtD
Salbutamol—Vertigo—Methotrexate—stomach cancer	0.000112	0.00063	CcSEcCtD
Salbutamol—Gastrointestinal pain—Capecitabine—stomach cancer	0.000111	0.000628	CcSEcCtD
Salbutamol—Mediastinal disorder—Doxorubicin—stomach cancer	0.000111	0.000628	CcSEcCtD
Salbutamol—Abdominal pain—Docetaxel—stomach cancer	0.000111	0.000628	CcSEcCtD
Salbutamol—Body temperature increased—Docetaxel—stomach cancer	0.000111	0.000628	CcSEcCtD
Salbutamol—Chills—Doxorubicin—stomach cancer	0.000111	0.000626	CcSEcCtD
Salbutamol—Arrhythmia—Doxorubicin—stomach cancer	0.00011	0.000623	CcSEcCtD
Salbutamol—Cough—Methotrexate—stomach cancer	0.000108	0.000612	CcSEcCtD
Salbutamol—Mental disorder—Doxorubicin—stomach cancer	0.000108	0.000611	CcSEcCtD
Salbutamol—Urticaria—Capecitabine—stomach cancer	0.000108	0.000611	CcSEcCtD
Salbutamol—Ill-defined disorder—Epirubicin—stomach cancer	0.000108	0.000609	CcSEcCtD
Salbutamol—Abdominal pain—Capecitabine—stomach cancer	0.000108	0.000608	CcSEcCtD
Salbutamol—Body temperature increased—Capecitabine—stomach cancer	0.000108	0.000608	CcSEcCtD
Salbutamol—Malnutrition—Doxorubicin—stomach cancer	0.000108	0.000607	CcSEcCtD
Salbutamol—Agitation—Epirubicin—stomach cancer	0.000107	0.000603	CcSEcCtD
Salbutamol—Flatulence—Doxorubicin—stomach cancer	0.000106	0.000598	CcSEcCtD
Salbutamol—Chest pain—Methotrexate—stomach cancer	0.000106	0.000597	CcSEcCtD
Salbutamol—Arthralgia—Methotrexate—stomach cancer	0.000106	0.000597	CcSEcCtD
Salbutamol—Myalgia—Methotrexate—stomach cancer	0.000106	0.000597	CcSEcCtD
Salbutamol—Tension—Doxorubicin—stomach cancer	0.000105	0.000596	CcSEcCtD
Salbutamol—Dysgeusia—Doxorubicin—stomach cancer	0.000105	0.000594	CcSEcCtD
Salbutamol—Malaise—Epirubicin—stomach cancer	0.000105	0.000592	CcSEcCtD
Salbutamol—Discomfort—Methotrexate—stomach cancer	0.000104	0.00059	CcSEcCtD
Salbutamol—Nervousness—Doxorubicin—stomach cancer	0.000104	0.00059	CcSEcCtD
Salbutamol—Vertigo—Epirubicin—stomach cancer	0.000104	0.000589	CcSEcCtD
Salbutamol—Syncope—Epirubicin—stomach cancer	0.000104	0.000588	CcSEcCtD
Salbutamol—Back pain—Doxorubicin—stomach cancer	0.000104	0.000587	CcSEcCtD
Salbutamol—Hypersensitivity—Docetaxel—stomach cancer	0.000104	0.000585	CcSEcCtD
Salbutamol—Muscle spasms—Doxorubicin—stomach cancer	0.000103	0.000584	CcSEcCtD
Salbutamol—Palpitations—Epirubicin—stomach cancer	0.000103	0.00058	CcSEcCtD
Salbutamol—Loss of consciousness—Epirubicin—stomach cancer	0.000102	0.000577	CcSEcCtD
Salbutamol—Cough—Epirubicin—stomach cancer	0.000101	0.000573	CcSEcCtD
Salbutamol—Anaphylactic shock—Methotrexate—stomach cancer	0.000101	0.000572	CcSEcCtD
Salbutamol—Asthenia—Docetaxel—stomach cancer	0.000101	0.00057	CcSEcCtD
Salbutamol—Infection—Methotrexate—stomach cancer	0.000101	0.000568	CcSEcCtD
Salbutamol—Hypertension—Epirubicin—stomach cancer	0.0001	0.000566	CcSEcCtD
Salbutamol—Hypersensitivity—Capecitabine—stomach cancer	0.0001	0.000566	CcSEcCtD
Salbutamol—Ill-defined disorder—Doxorubicin—stomach cancer	9.97e-05	0.000563	CcSEcCtD
Salbutamol—Pruritus—Docetaxel—stomach cancer	9.95e-05	0.000562	CcSEcCtD
Salbutamol—Nervous system disorder—Methotrexate—stomach cancer	9.94e-05	0.000561	CcSEcCtD
Salbutamol—Arthralgia—Epirubicin—stomach cancer	9.89e-05	0.000559	CcSEcCtD
Salbutamol—Chest pain—Epirubicin—stomach cancer	9.89e-05	0.000559	CcSEcCtD
Salbutamol—Myalgia—Epirubicin—stomach cancer	9.89e-05	0.000559	CcSEcCtD
Salbutamol—Agitation—Doxorubicin—stomach cancer	9.88e-05	0.000558	CcSEcCtD
Salbutamol—Anxiety—Epirubicin—stomach cancer	9.86e-05	0.000557	CcSEcCtD
Salbutamol—Skin disorder—Methotrexate—stomach cancer	9.84e-05	0.000556	CcSEcCtD
Salbutamol—Hyperhidrosis—Methotrexate—stomach cancer	9.8e-05	0.000553	CcSEcCtD
Salbutamol—Discomfort—Epirubicin—stomach cancer	9.77e-05	0.000552	CcSEcCtD
Salbutamol—Asthenia—Capecitabine—stomach cancer	9.77e-05	0.000551	CcSEcCtD
Salbutamol—Malaise—Doxorubicin—stomach cancer	9.69e-05	0.000547	CcSEcCtD
Salbutamol—Dry mouth—Epirubicin—stomach cancer	9.67e-05	0.000546	CcSEcCtD
Salbutamol—Vertigo—Doxorubicin—stomach cancer	9.66e-05	0.000545	CcSEcCtD
Salbutamol—Anorexia—Methotrexate—stomach cancer	9.66e-05	0.000545	CcSEcCtD
Salbutamol—Syncope—Doxorubicin—stomach cancer	9.64e-05	0.000544	CcSEcCtD
Salbutamol—Pruritus—Capecitabine—stomach cancer	9.63e-05	0.000544	CcSEcCtD
Salbutamol—Diarrhoea—Docetaxel—stomach cancer	9.62e-05	0.000543	CcSEcCtD
Salbutamol—Palpitations—Doxorubicin—stomach cancer	9.5e-05	0.000536	CcSEcCtD
Salbutamol—Anaphylactic shock—Epirubicin—stomach cancer	9.48e-05	0.000535	CcSEcCtD
Salbutamol—Oedema—Epirubicin—stomach cancer	9.48e-05	0.000535	CcSEcCtD
Salbutamol—Hypotension—Methotrexate—stomach cancer	9.47e-05	0.000535	CcSEcCtD
Salbutamol—Loss of consciousness—Doxorubicin—stomach cancer	9.45e-05	0.000534	CcSEcCtD
Salbutamol—Infection—Epirubicin—stomach cancer	9.42e-05	0.000532	CcSEcCtD
Salbutamol—Cough—Doxorubicin—stomach cancer	9.38e-05	0.00053	CcSEcCtD
Salbutamol—Shock—Epirubicin—stomach cancer	9.33e-05	0.000527	CcSEcCtD
Salbutamol—Diarrhoea—Capecitabine—stomach cancer	9.31e-05	0.000526	CcSEcCtD
Salbutamol—Nervous system disorder—Epirubicin—stomach cancer	9.3e-05	0.000525	CcSEcCtD
Salbutamol—Dizziness—Docetaxel—stomach cancer	9.3e-05	0.000525	CcSEcCtD
Salbutamol—Hypertension—Doxorubicin—stomach cancer	9.28e-05	0.000524	CcSEcCtD
Salbutamol—Tachycardia—Epirubicin—stomach cancer	9.25e-05	0.000523	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Methotrexate—stomach cancer	9.23e-05	0.000521	CcSEcCtD
Salbutamol—Skin disorder—Epirubicin—stomach cancer	9.21e-05	0.00052	CcSEcCtD
Salbutamol—Hyperhidrosis—Epirubicin—stomach cancer	9.17e-05	0.000518	CcSEcCtD
Salbutamol—Insomnia—Methotrexate—stomach cancer	9.16e-05	0.000517	CcSEcCtD
Salbutamol—Chest pain—Doxorubicin—stomach cancer	9.15e-05	0.000517	CcSEcCtD
Salbutamol—Myalgia—Doxorubicin—stomach cancer	9.15e-05	0.000517	CcSEcCtD
Salbutamol—Arthralgia—Doxorubicin—stomach cancer	9.15e-05	0.000517	CcSEcCtD
Salbutamol—Anxiety—Doxorubicin—stomach cancer	9.12e-05	0.000515	CcSEcCtD
Salbutamol—Paraesthesia—Methotrexate—stomach cancer	9.1e-05	0.000514	CcSEcCtD
Salbutamol—Discomfort—Doxorubicin—stomach cancer	9.04e-05	0.000511	CcSEcCtD
Salbutamol—Anorexia—Epirubicin—stomach cancer	9.04e-05	0.00051	CcSEcCtD
Salbutamol—Dyspnoea—Methotrexate—stomach cancer	9.03e-05	0.00051	CcSEcCtD
Salbutamol—Somnolence—Methotrexate—stomach cancer	9.01e-05	0.000509	CcSEcCtD
Salbutamol—Dizziness—Capecitabine—stomach cancer	9e-05	0.000508	CcSEcCtD
Salbutamol—Dry mouth—Doxorubicin—stomach cancer	8.95e-05	0.000505	CcSEcCtD
Salbutamol—Vomiting—Docetaxel—stomach cancer	8.94e-05	0.000505	CcSEcCtD
Salbutamol—Dyspepsia—Methotrexate—stomach cancer	8.92e-05	0.000504	CcSEcCtD
Salbutamol—Rash—Docetaxel—stomach cancer	8.86e-05	0.000501	CcSEcCtD
Salbutamol—Hypotension—Epirubicin—stomach cancer	8.86e-05	0.0005	CcSEcCtD
Salbutamol—Dermatitis—Docetaxel—stomach cancer	8.86e-05	0.0005	CcSEcCtD
Salbutamol—Decreased appetite—Methotrexate—stomach cancer	8.81e-05	0.000497	CcSEcCtD
Salbutamol—Headache—Docetaxel—stomach cancer	8.81e-05	0.000497	CcSEcCtD
Salbutamol—Oedema—Doxorubicin—stomach cancer	8.77e-05	0.000495	CcSEcCtD
Salbutamol—Anaphylactic shock—Doxorubicin—stomach cancer	8.77e-05	0.000495	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Methotrexate—stomach cancer	8.75e-05	0.000494	CcSEcCtD
Salbutamol—Fatigue—Methotrexate—stomach cancer	8.74e-05	0.000493	CcSEcCtD
Salbutamol—Infection—Doxorubicin—stomach cancer	8.72e-05	0.000492	CcSEcCtD
Salbutamol—Pain—Methotrexate—stomach cancer	8.67e-05	0.000489	CcSEcCtD
Salbutamol—Vomiting—Capecitabine—stomach cancer	8.65e-05	0.000489	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Epirubicin—stomach cancer	8.64e-05	0.000488	CcSEcCtD
Salbutamol—Shock—Doxorubicin—stomach cancer	8.63e-05	0.000487	CcSEcCtD
Salbutamol—Nervous system disorder—Doxorubicin—stomach cancer	8.6e-05	0.000486	CcSEcCtD
Salbutamol—Rash—Capecitabine—stomach cancer	8.58e-05	0.000485	CcSEcCtD
Salbutamol—Insomnia—Epirubicin—stomach cancer	8.58e-05	0.000484	CcSEcCtD
Salbutamol—Dermatitis—Capecitabine—stomach cancer	8.57e-05	0.000484	CcSEcCtD
Salbutamol—Tachycardia—Doxorubicin—stomach cancer	8.56e-05	0.000484	CcSEcCtD
Salbutamol—Headache—Capecitabine—stomach cancer	8.53e-05	0.000481	CcSEcCtD
Salbutamol—Skin disorder—Doxorubicin—stomach cancer	8.52e-05	0.000481	CcSEcCtD
Salbutamol—Paraesthesia—Epirubicin—stomach cancer	8.51e-05	0.000481	CcSEcCtD
Salbutamol—Hyperhidrosis—Doxorubicin—stomach cancer	8.48e-05	0.000479	CcSEcCtD
Salbutamol—Dyspnoea—Epirubicin—stomach cancer	8.45e-05	0.000477	CcSEcCtD
Salbutamol—Somnolence—Epirubicin—stomach cancer	8.43e-05	0.000476	CcSEcCtD
Salbutamol—Anorexia—Doxorubicin—stomach cancer	8.36e-05	0.000472	CcSEcCtD
Salbutamol—Nausea—Docetaxel—stomach cancer	8.35e-05	0.000472	CcSEcCtD
Salbutamol—Feeling abnormal—Methotrexate—stomach cancer	8.35e-05	0.000471	CcSEcCtD
Salbutamol—Dyspepsia—Epirubicin—stomach cancer	8.35e-05	0.000471	CcSEcCtD
Salbutamol—Gastrointestinal pain—Methotrexate—stomach cancer	8.29e-05	0.000468	CcSEcCtD
Salbutamol—Decreased appetite—Epirubicin—stomach cancer	8.24e-05	0.000465	CcSEcCtD
Salbutamol—Hypotension—Doxorubicin—stomach cancer	8.2e-05	0.000463	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Epirubicin—stomach cancer	8.19e-05	0.000462	CcSEcCtD
Salbutamol—Fatigue—Epirubicin—stomach cancer	8.18e-05	0.000462	CcSEcCtD
Salbutamol—Pain—Epirubicin—stomach cancer	8.11e-05	0.000458	CcSEcCtD
Salbutamol—Constipation—Epirubicin—stomach cancer	8.11e-05	0.000458	CcSEcCtD
Salbutamol—Nausea—Capecitabine—stomach cancer	8.09e-05	0.000457	CcSEcCtD
Salbutamol—Urticaria—Methotrexate—stomach cancer	8.05e-05	0.000455	CcSEcCtD
Salbutamol—Abdominal pain—Methotrexate—stomach cancer	8.01e-05	0.000452	CcSEcCtD
Salbutamol—Body temperature increased—Methotrexate—stomach cancer	8.01e-05	0.000452	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Doxorubicin—stomach cancer	7.99e-05	0.000451	CcSEcCtD
Salbutamol—Insomnia—Doxorubicin—stomach cancer	7.94e-05	0.000448	CcSEcCtD
Salbutamol—Paraesthesia—Doxorubicin—stomach cancer	7.88e-05	0.000445	CcSEcCtD
Salbutamol—Dyspnoea—Doxorubicin—stomach cancer	7.82e-05	0.000442	CcSEcCtD
Salbutamol—Feeling abnormal—Epirubicin—stomach cancer	7.81e-05	0.000441	CcSEcCtD
Salbutamol—Somnolence—Doxorubicin—stomach cancer	7.8e-05	0.00044	CcSEcCtD
Salbutamol—Gastrointestinal pain—Epirubicin—stomach cancer	7.75e-05	0.000438	CcSEcCtD
Salbutamol—Dyspepsia—Doxorubicin—stomach cancer	7.72e-05	0.000436	CcSEcCtD
Salbutamol—Decreased appetite—Doxorubicin—stomach cancer	7.63e-05	0.000431	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Doxorubicin—stomach cancer	7.57e-05	0.000428	CcSEcCtD
Salbutamol—Fatigue—Doxorubicin—stomach cancer	7.56e-05	0.000427	CcSEcCtD
Salbutamol—Urticaria—Epirubicin—stomach cancer	7.53e-05	0.000425	CcSEcCtD
Salbutamol—Pain—Doxorubicin—stomach cancer	7.5e-05	0.000424	CcSEcCtD
Salbutamol—Constipation—Doxorubicin—stomach cancer	7.5e-05	0.000424	CcSEcCtD
Salbutamol—Abdominal pain—Epirubicin—stomach cancer	7.5e-05	0.000423	CcSEcCtD
Salbutamol—Body temperature increased—Epirubicin—stomach cancer	7.5e-05	0.000423	CcSEcCtD
Salbutamol—Hypersensitivity—Methotrexate—stomach cancer	7.47e-05	0.000422	CcSEcCtD
Salbutamol—Asthenia—Methotrexate—stomach cancer	7.27e-05	0.000411	CcSEcCtD
Salbutamol—Feeling abnormal—Doxorubicin—stomach cancer	7.23e-05	0.000408	CcSEcCtD
Salbutamol—Gastrointestinal pain—Doxorubicin—stomach cancer	7.17e-05	0.000405	CcSEcCtD
Salbutamol—Pruritus—Methotrexate—stomach cancer	7.17e-05	0.000405	CcSEcCtD
Salbutamol—Hypersensitivity—Epirubicin—stomach cancer	6.99e-05	0.000394	CcSEcCtD
Salbutamol—Urticaria—Doxorubicin—stomach cancer	6.97e-05	0.000394	CcSEcCtD
Salbutamol—Abdominal pain—Doxorubicin—stomach cancer	6.94e-05	0.000392	CcSEcCtD
Salbutamol—Body temperature increased—Doxorubicin—stomach cancer	6.94e-05	0.000392	CcSEcCtD
Salbutamol—Diarrhoea—Methotrexate—stomach cancer	6.93e-05	0.000391	CcSEcCtD
Salbutamol—Asthenia—Epirubicin—stomach cancer	6.8e-05	0.000384	CcSEcCtD
Salbutamol—Pruritus—Epirubicin—stomach cancer	6.71e-05	0.000379	CcSEcCtD
Salbutamol—Dizziness—Methotrexate—stomach cancer	6.7e-05	0.000378	CcSEcCtD
Salbutamol—Diarrhoea—Epirubicin—stomach cancer	6.49e-05	0.000366	CcSEcCtD
Salbutamol—Hypersensitivity—Doxorubicin—stomach cancer	6.46e-05	0.000365	CcSEcCtD
Salbutamol—Vomiting—Methotrexate—stomach cancer	6.44e-05	0.000364	CcSEcCtD
Salbutamol—Rash—Methotrexate—stomach cancer	6.39e-05	0.000361	CcSEcCtD
Salbutamol—Dermatitis—Methotrexate—stomach cancer	6.38e-05	0.00036	CcSEcCtD
Salbutamol—Headache—Methotrexate—stomach cancer	6.35e-05	0.000358	CcSEcCtD
Salbutamol—Asthenia—Doxorubicin—stomach cancer	6.3e-05	0.000355	CcSEcCtD
Salbutamol—Dizziness—Epirubicin—stomach cancer	6.27e-05	0.000354	CcSEcCtD
Salbutamol—Pruritus—Doxorubicin—stomach cancer	6.21e-05	0.000351	CcSEcCtD
Salbutamol—Vomiting—Epirubicin—stomach cancer	6.03e-05	0.00034	CcSEcCtD
Salbutamol—Nausea—Methotrexate—stomach cancer	6.02e-05	0.00034	CcSEcCtD
Salbutamol—Diarrhoea—Doxorubicin—stomach cancer	6e-05	0.000339	CcSEcCtD
Salbutamol—Rash—Epirubicin—stomach cancer	5.98e-05	0.000338	CcSEcCtD
Salbutamol—Dermatitis—Epirubicin—stomach cancer	5.97e-05	0.000337	CcSEcCtD
Salbutamol—Headache—Epirubicin—stomach cancer	5.94e-05	0.000335	CcSEcCtD
Salbutamol—Dizziness—Doxorubicin—stomach cancer	5.8e-05	0.000328	CcSEcCtD
Salbutamol—Nausea—Epirubicin—stomach cancer	5.63e-05	0.000318	CcSEcCtD
Salbutamol—Vomiting—Doxorubicin—stomach cancer	5.58e-05	0.000315	CcSEcCtD
Salbutamol—Rash—Doxorubicin—stomach cancer	5.53e-05	0.000312	CcSEcCtD
Salbutamol—Dermatitis—Doxorubicin—stomach cancer	5.53e-05	0.000312	CcSEcCtD
Salbutamol—Headache—Doxorubicin—stomach cancer	5.5e-05	0.00031	CcSEcCtD
Salbutamol—Nausea—Doxorubicin—stomach cancer	5.21e-05	0.000294	CcSEcCtD
Salbutamol—ADRB2—GPCR ligand binding—HTR1A—stomach cancer	7.3e-06	0.00266	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ANXA1—stomach cancer	7.2e-06	0.00262	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ANXA1—stomach cancer	7.05e-06	0.00257	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRH4—stomach cancer	6.85e-06	0.00249	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ADRB1—stomach cancer	6.82e-06	0.00248	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—KISS1—stomach cancer	6.72e-06	0.00245	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRH4—stomach cancer	6.7e-06	0.00244	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—KISS1—stomach cancer	6.57e-06	0.00239	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KISS1—stomach cancer	6.1e-06	0.00222	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KISS1—stomach cancer	5.97e-06	0.00217	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—RGS2—stomach cancer	5.78e-06	0.0021	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GAST—stomach cancer	5.78e-06	0.0021	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADRB2—stomach cancer	5.65e-06	0.00206	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—RGS2—stomach cancer	5.65e-06	0.00206	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GAST—stomach cancer	5.65e-06	0.00206	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KISS1R—stomach cancer	5.59e-06	0.00204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GLI3—stomach cancer	5.59e-06	0.00204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KISS1R—stomach cancer	5.47e-06	0.00199	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GLI3—stomach cancer	5.47e-06	0.00199	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RBP1—stomach cancer	5.34e-06	0.00194	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTT1—stomach cancer	5.32e-06	0.00194	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP2A6—stomach cancer	5.26e-06	0.00192	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—RGS2—stomach cancer	5.25e-06	0.00191	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GAST—stomach cancer	5.25e-06	0.00191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RBP1—stomach cancer	5.22e-06	0.0019	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—RGS2—stomach cancer	5.13e-06	0.00187	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GAST—stomach cancer	5.13e-06	0.00187	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—AKR1C3—stomach cancer	5.05e-06	0.00184	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AGTR2—stomach cancer	4.38e-06	0.00159	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—WWOX—stomach cancer	4.35e-06	0.00158	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—F2R—stomach cancer	4.33e-06	0.00158	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AGTR2—stomach cancer	4.28e-06	0.00156	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—WWOX—stomach cancer	4.26e-06	0.00155	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—F2R—stomach cancer	4.24e-06	0.00154	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR1A—stomach cancer	4.22e-06	0.00153	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR1A—stomach cancer	4.12e-06	0.0015	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ANXA1—stomach cancer	4.07e-06	0.00148	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—WIF1—stomach cancer	4.04e-06	0.00147	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRH4—stomach cancer	4.04e-06	0.00147	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ANXA1—stomach cancer	3.98e-06	0.00145	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AGTR2—stomach cancer	3.98e-06	0.00145	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—WIF1—stomach cancer	3.96e-06	0.00144	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRH4—stomach cancer	3.96e-06	0.00144	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—F2R—stomach cancer	3.93e-06	0.00143	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AGTR2—stomach cancer	3.89e-06	0.00142	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADRB1—stomach cancer	3.86e-06	0.0014	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—F2R—stomach cancer	3.85e-06	0.0014	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR1A—stomach cancer	3.83e-06	0.00139	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR1A—stomach cancer	3.74e-06	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKAB1—stomach cancer	3.73e-06	0.00136	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ANXA1—stomach cancer	3.7e-06	0.00135	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTP1—stomach cancer	3.69e-06	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKAB1—stomach cancer	3.65e-06	0.00133	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTP1—stomach cancer	3.64e-06	0.00132	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ANXA1—stomach cancer	3.62e-06	0.00132	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KISS1—stomach cancer	3.6e-06	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RNF43—stomach cancer	3.6e-06	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	3.59e-06	0.00131	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RNF43—stomach cancer	3.53e-06	0.00128	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KISS1—stomach cancer	3.53e-06	0.00128	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	3.51e-06	0.00128	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADRB1—stomach cancer	3.5e-06	0.00128	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTM1—stomach cancer	3.39e-06	0.00123	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTM1—stomach cancer	3.34e-06	0.00122	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FST—stomach cancer	3.21e-06	0.00117	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADRB2—stomach cancer	3.19e-06	0.00116	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ACAD8—stomach cancer	3.17e-06	0.00115	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HBEGF—stomach cancer	3.14e-06	0.00114	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FST—stomach cancer	3.14e-06	0.00114	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RGS2—stomach cancer	3.1e-06	0.00113	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GAST—stomach cancer	3.1e-06	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HBEGF—stomach cancer	3.07e-06	0.00112	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RGS2—stomach cancer	3.03e-06	0.0011	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GAST—stomach cancer	3.03e-06	0.0011	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGG—stomach cancer	2.94e-06	0.00107	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADRB2—stomach cancer	2.9e-06	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGG—stomach cancer	2.87e-06	0.00105	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PPP2R1A—stomach cancer	2.84e-06	0.00104	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKAA1—stomach cancer	2.83e-06	0.00103	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GMPR2—stomach cancer	2.83e-06	0.00103	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PPP2R1A—stomach cancer	2.78e-06	0.00101	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKAA1—stomach cancer	2.77e-06	0.00101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RBP4—stomach cancer	2.73e-06	0.000995	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—stomach cancer	2.73e-06	0.000994	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RBP4—stomach cancer	2.67e-06	0.000973	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—stomach cancer	2.67e-06	0.000972	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—IDH3B—stomach cancer	2.59e-06	0.000941	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SUCLG1—stomach cancer	2.59e-06	0.000941	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NDUFS1—stomach cancer	2.4e-06	0.000875	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NDUFV1—stomach cancer	2.4e-06	0.000875	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HSPB1—stomach cancer	2.35e-06	0.000855	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AGTR2—stomach cancer	2.35e-06	0.000855	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BMP2—stomach cancer	2.32e-06	0.000846	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—F2R—stomach cancer	2.32e-06	0.000846	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HSPB1—stomach cancer	2.3e-06	0.000837	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AGTR2—stomach cancer	2.3e-06	0.000837	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKR1C3—stomach cancer	2.29e-06	0.000832	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BMP2—stomach cancer	2.27e-06	0.000827	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—F2R—stomach cancer	2.27e-06	0.000827	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR1A—stomach cancer	2.26e-06	0.000823	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKR1C3—stomach cancer	2.24e-06	0.000814	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR1A—stomach cancer	2.21e-06	0.000805	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PRKCB—stomach cancer	2.19e-06	0.000797	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ANXA1—stomach cancer	2.18e-06	0.000795	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BLVRB—stomach cancer	2.14e-06	0.00078	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PGLS—stomach cancer	2.14e-06	0.00078	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PRKCB—stomach cancer	2.14e-06	0.00078	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ANXA1—stomach cancer	2.14e-06	0.000778	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADRB1—stomach cancer	2.07e-06	0.000753	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPAP2A—stomach cancer	2.04e-06	0.000744	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RPS6—stomach cancer	2.02e-06	0.000736	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PRKCB—stomach cancer	1.99e-06	0.000724	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6ST—stomach cancer	1.98e-06	0.000721	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RPS6—stomach cancer	1.98e-06	0.00072	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PRKCB—stomach cancer	1.94e-06	0.000708	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6ST—stomach cancer	1.94e-06	0.000705	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HBEGF—stomach cancer	1.86e-06	0.000676	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA1—stomach cancer	1.82e-06	0.000663	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FBP1—stomach cancer	1.82e-06	0.000663	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CKB—stomach cancer	1.82e-06	0.000663	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NDUFA2—stomach cancer	1.82e-06	0.000663	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HBEGF—stomach cancer	1.82e-06	0.000661	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6R—stomach cancer	1.77e-06	0.000643	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—RHOA—stomach cancer	1.76e-06	0.00064	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6R—stomach cancer	1.73e-06	0.000629	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—RHOA—stomach cancer	1.72e-06	0.000626	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADRB2—stomach cancer	1.71e-06	0.000624	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLIN2—stomach cancer	1.71e-06	0.000624	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPP2R1A—stomach cancer	1.68e-06	0.000611	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA2—stomach cancer	1.67e-06	0.000607	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPP2R1A—stomach cancer	1.64e-06	0.000598	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PGAM1—stomach cancer	1.62e-06	0.000591	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NT5E—stomach cancer	1.62e-06	0.000591	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—RHOA—stomach cancer	1.6e-06	0.000581	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—RHOA—stomach cancer	1.56e-06	0.000568	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SMAD4—stomach cancer	1.56e-06	0.000568	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDH7A1—stomach cancer	1.55e-06	0.000564	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLCE1—stomach cancer	1.55e-06	0.000564	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—stomach cancer	1.54e-06	0.000562	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SMAD4—stomach cancer	1.53e-06	0.000555	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—stomach cancer	1.51e-06	0.000549	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UMPS—stomach cancer	1.49e-06	0.000541	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FYN—stomach cancer	1.48e-06	0.000539	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FYN—stomach cancer	1.45e-06	0.000527	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—stomach cancer	1.4e-06	0.00051	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGFR2—stomach cancer	1.39e-06	0.000506	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PDHA1—stomach cancer	1.38e-06	0.000503	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ECHS1—stomach cancer	1.38e-06	0.000503	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—stomach cancer	1.37e-06	0.000499	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGFR2—stomach cancer	1.36e-06	0.000495	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMP—stomach cancer	1.3e-06	0.000473	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—FADS1—stomach cancer	1.3e-06	0.000473	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IRS2—stomach cancer	1.27e-06	0.000463	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IRS2—stomach cancer	1.24e-06	0.000453	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CAV1—stomach cancer	1.23e-06	0.000449	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA1—stomach cancer	1.23e-06	0.000448	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SREBF2—stomach cancer	1.22e-06	0.000443	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CAV1—stomach cancer	1.21e-06	0.000439	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA1—stomach cancer	1.2e-06	0.000438	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—RORA—stomach cancer	1.2e-06	0.000437	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PRKCB—stomach cancer	1.17e-06	0.000428	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6ST—stomach cancer	1.17e-06	0.000426	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PRKCB—stomach cancer	1.15e-06	0.000418	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6ST—stomach cancer	1.14e-06	0.000417	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDOB—stomach cancer	1.13e-06	0.00041	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APC—stomach cancer	1.12e-06	0.000409	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APC—stomach cancer	1.1e-06	0.0004	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK3—stomach cancer	1.08e-06	0.000392	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK3—stomach cancer	1.05e-06	0.000383	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX5—stomach cancer	1.05e-06	0.000381	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6R—stomach cancer	1.04e-06	0.00038	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—DPYD—stomach cancer	1.03e-06	0.000375	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK1—stomach cancer	1.02e-06	0.000373	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—stomach cancer	1.02e-06	0.000373	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6R—stomach cancer	1.02e-06	0.000372	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK1—stomach cancer	1e-06	0.000365	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—stomach cancer	1e-06	0.000365	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—stomach cancer	9.79e-07	0.000356	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SERPINE1—stomach cancer	9.77e-07	0.000356	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—stomach cancer	9.67e-07	0.000352	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—stomach cancer	9.57e-07	0.000349	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SERPINE1—stomach cancer	9.56e-07	0.000348	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—stomach cancer	9.46e-07	0.000345	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RHOA—stomach cancer	9.43e-07	0.000343	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—stomach cancer	9.33e-07	0.00034	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RHOA—stomach cancer	9.22e-07	0.000336	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—stomach cancer	9.13e-07	0.000332	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—stomach cancer	9.1e-07	0.000331	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2A6—stomach cancer	9e-07	0.000328	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—stomach cancer	8.89e-07	0.000324	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C3—stomach cancer	8.75e-07	0.000319	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB2—stomach cancer	8.73e-07	0.000318	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—stomach cancer	8.69e-07	0.000317	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB2—stomach cancer	8.54e-07	0.000311	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENO1—stomach cancer	8.53e-07	0.000311	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—stomach cancer	8.28e-07	0.000301	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRAS—stomach cancer	8.22e-07	0.000299	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—stomach cancer	8.1e-07	0.000295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1B—stomach cancer	8.08e-07	0.000294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRAS—stomach cancer	8.04e-07	0.000293	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1B—stomach cancer	7.91e-07	0.000288	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—stomach cancer	7.87e-07	0.000287	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—stomach cancer	7.71e-07	0.000281	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—stomach cancer	7.7e-07	0.00028	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUN—stomach cancer	7.69e-07	0.00028	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CD44—stomach cancer	7.57e-07	0.000275	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—stomach cancer	7.54e-07	0.000275	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUN—stomach cancer	7.53e-07	0.000274	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—stomach cancer	7.49e-07	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—stomach cancer	7.46e-07	0.000272	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—stomach cancer	7.32e-07	0.000267	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—stomach cancer	7.3e-07	0.000266	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK8—stomach cancer	7.28e-07	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK8—stomach cancer	7.12e-07	0.000259	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—stomach cancer	6.72e-07	0.000245	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—stomach cancer	6.66e-07	0.000242	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—stomach cancer	6.58e-07	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—stomach cancer	6.51e-07	0.000237	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPP2R1A—stomach cancer	6.43e-07	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK3—stomach cancer	6.36e-07	0.000232	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—stomach cancer	6.31e-07	0.00023	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—stomach cancer	6.22e-07	0.000227	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK3—stomach cancer	6.22e-07	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—stomach cancer	6.18e-07	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK1—stomach cancer	6.05e-07	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—stomach cancer	6.05e-07	0.00022	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—stomach cancer	6.05e-07	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK1—stomach cancer	5.92e-07	0.000215	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—stomach cancer	5.92e-07	0.000215	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMS—stomach cancer	5.87e-07	0.000214	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—stomach cancer	5.8e-07	0.000211	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—stomach cancer	5.71e-07	0.000208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—stomach cancer	5.59e-07	0.000204	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ERCC2—stomach cancer	5.45e-07	0.000198	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—stomach cancer	5.25e-07	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—stomach cancer	5.14e-07	0.000187	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTHFR—stomach cancer	5.12e-07	0.000187	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—stomach cancer	5.08e-07	0.000185	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—stomach cancer	4.97e-07	0.000181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRAS—stomach cancer	4.86e-07	0.000177	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRAS—stomach cancer	4.75e-07	0.000173	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAV1—stomach cancer	4.73e-07	0.000172	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA1—stomach cancer	4.72e-07	0.000172	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—stomach cancer	4.65e-07	0.000169	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—stomach cancer	4.55e-07	0.000166	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPARG—stomach cancer	4.16e-07	0.000151	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—stomach cancer	3.74e-07	0.000136	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—stomach cancer	3.57e-07	0.00013	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—stomach cancer	3.27e-07	0.000119	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—stomach cancer	2.01e-07	7.32e-05	CbGpPWpGaD
